{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T22:34:30Z","timestamp":1764714870662,"version":"3.41.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10067-018-4018-1","type":"journal-article","created":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T04:35:04Z","timestamp":1521606904000},"page":"1729-1735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report"],"prefix":"10.1007","volume":"37","author":[{"given":"Tatiana V.","family":"Beketova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7577-2994","authenticated-orcid":false,"given":"Mikhail Y.","family":"Volkov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeniy A.","family":"Naryshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana M.","family":"Novoselova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeniy L.","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"issue":"1","key":"4018_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Pu\u00e9chal X, Auma\u00eetre O, Guenno GL, Quellec AL, Cevallos R, Fain O, Godeau B, Seror R, Dunogu\u00e9 B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L, for the French Vasculitis Study Group (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65(1):270\u2013281. https:\/\/doi.org\/10.1002\/art.37721","journal-title":"Arthritis Rheum"},{"issue":"7","key":"4018_CR2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, Dalhoff K, Dunogu\u00e9 B, Gross W, Holle J, Humbert M, Jayne D, Jennette JC, Lazor R, Mahr A, Merkel PA, Mouthon L, Sinico RA, Specks U, Vaglio A, Wechsler ME, Cordier JF, Guillevin L (2015) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 26(7):545\u2013553. https:\/\/doi.org\/10.1016\/j.ejim.2015.04.022","journal-title":"Eur J Intern Med"},{"issue":"2","key":"4018_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry M-J, Amudala N, Smith R, Sivasothy P, Guillevin L, Merkel PA, Jayne DRW (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). Ann Rheum Dis 75(2):396\u2013401. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206095","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"4018_CR4","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.39663","volume":"68","author":"M Jachiet","year":"2016","unstructured":"Jachiet M, Samson M, Cottin V, Kahn JE, Le Guenno G, Bonniaud P et al (2016) Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): data on seventeen patients. Arthritis Rheumatol 68(9):2274\u20132282. https:\/\/doi.org\/10.1002\/art.39663","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"4018_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","volume":"53","author":"A Detoraki","year":"2016","unstructured":"Detoraki A, Di Capua L, Varricchi G, Genovese A, Marone G, Spadaro G (2016) Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma 53(2):201\u2013206. https:\/\/doi.org\/10.3109\/02770903.2015.1081700","journal-title":"J Asthma"},{"issue":"9","key":"4018_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s10067-017-3780-9","volume":"36","author":"D Aguirre-Valencia","year":"2017","unstructured":"Aguirre-Valencia D, Posso-Osorio I, Bravo JC, Bonilla-Abad\u00eda F, Tob\u00f3n GJ, Ca\u00f1as CA (2017) Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Clin Rheumatol 36(9):2159\u20132162. https:\/\/doi.org\/10.1007\/s10067-017-3780-9","journal-title":"Clin Rheumatol"},{"issue":"5","key":"4018_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","volume":"143","author":"G Metzgeroth","year":"2008","unstructured":"Metzgeroth G, Walz C, Erben P, Popp H, Schmitt-Graeff A, Haferlach C, Fabarius A, Schnittger S, Grimwade D, Cross NCP, Hehlmann R, Hochhaus A, Reiter A (2008) Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome\u2014a phase-II study. Br J Haematol 143(5):707\u2013715. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07294.x","journal-title":"Br J Haematol"},{"issue":"3","key":"4018_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1872213X113079990021","volume":"7","author":"G Azizi","year":"2013","unstructured":"Azizi G, Mirshafiey A (2013) Imatinib mesylate: an innovation in treatment of autoimmune diseases. Recent Pat Inflamm Allergy Drug Discov 7(3):259\u2013267. https:\/\/doi.org\/10.2174\/1872213X113079990021","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"5","key":"4018_CR9","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1681\/ASN.2012080818","volume":"24","author":"E Wallace","year":"2013","unstructured":"Wallace E, Gewin L (2013) Imatinib: novel treatment of immune-mediated kidney injury. J Am Soc Nephrol 24(5):694\u2013701. https:\/\/doi.org\/10.1681\/ASN.2012080818","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4018_CR10","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1172\/JCI28546.","volume":"116","author":"RT Paniagua","year":"2006","unstructured":"Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116(10):2633\u20132642. https:\/\/doi.org\/10.1172\/JCI28546","journal-title":"J Clin Invest"},{"issue":"2","key":"4018_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1093\/rheumatology\/ket261","volume":"53","author":"L Josselin-Mahr","year":"2014","unstructured":"Josselin-Mahr L, Werbrouck-Chiraux A, Garderet L, Cabane J (2014) Efficacy of imatinib mesylate in a case of Churg\u2013Strauss syndrome: evidence for the pathogenic role of a tyrosine kinase? Rheumatology 53(2):378\u2013379. https:\/\/doi.org\/10.1093\/rheumatology\/ket261","journal-title":"Rheumatology"},{"issue":"1","key":"4018_CR12","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jbspin.2014.06.004","volume":"82","author":"GL Erre","year":"2015","unstructured":"Erre GL, Pardini S, Cuccuru L, Taras L, Passiu G (2015) Is there a role for imatinib mesylate in the treatment of eosinophilic granulomatosis with polyangiitis? Jt Bone Spine 82(1):72\u201373. https:\/\/doi.org\/10.1016\/j.jbspin.2014.06.004","journal-title":"Jt Bone Spine"},{"key":"4018_CR13","doi-asserted-by":"publisher","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, et al. (2017) The target landscape of clinical kinase drugs. Science 358:eaan4368. https:\/\/doi.org\/10.1126\/science.aan4368","DOI":"10.1126\/science.aan4368"},{"issue":"1","key":"4018_CR14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295(1):139\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4018_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1472-6807-9-7","volume":"9","author":"JA Winger","year":"2009","unstructured":"Winger JA, Hantschel O, Superti-Furga G, Kuriyan J (2009) The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol 9(1):1\u201312. https:\/\/doi.org\/10.1186\/1472-6807-9-7","journal-title":"BMC Struct Biol"},{"issue":"3","key":"4018_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/j.1365-2249.2007.03572.x","volume":"151","author":"AI K\u00e4lsch","year":"2008","unstructured":"K\u00e4lsch AI, Soboletzki M, Schmitt WH, Van Der Woude FJ, Hochhaus A, Yard BA et al (2008) Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis? Clin Exp Immunol 151(3):391\u2013398. https:\/\/doi.org\/10.1111\/j.1365-2249.2007.03572.x","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"4018_CR17","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lor\u00e9 K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A (2005) Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105(6):2473\u20132479. https:\/\/doi.org\/10.1182\/blood-2004-07-2527","journal-title":"Blood"},{"issue":"6","key":"4018_CR18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s00262-006-0232-9","volume":"56","author":"J Chen","year":"2007","unstructured":"Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, Von Harsdorf S et al (2007) Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM\/CD168 in vitro. Cancer Immunol Immunother 56(6):849\u2013861. https:\/\/doi.org\/10.1007\/s00262-006-0232-9","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"4018_CR19","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","volume":"105","author":"AL Dewar","year":"2005","unstructured":"Dewar AL, Cambareri AC, Zannettino ACW, Miller BL, Doherty KV, Hughes TP, Lyons AB (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105(8):3127\u20133132. https:\/\/doi.org\/10.1182\/blood-2004-10-3967","journal-title":"Blood"},{"issue":"3","key":"4018_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ijc.20305","volume":"111","author":"A Ohashi","year":"2004","unstructured":"Ohashi A, Kinoshita K, Isozaki K, Nishida T, Shinomura Y, Kitamura Y, Hirota S (2004) Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-alpha. Int J Cancer 111(3):317\u2013321. https:\/\/doi.org\/10.1002\/ijc.20305","journal-title":"Int J Cancer"},{"key":"4018_CR21","unstructured":"Hellmich B, Ehlers S, Csernok E, Gross WL (2003) Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 21(Suppl 32):S69\u201377"},{"key":"4018_CR22","doi-asserted-by":"publisher","unstructured":"Terrier B, Bi\u00e8che I, Maisonobe T, Laurendeau I, Rosenzwajg M, Kahn J-E, et al. (2010) IL-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood 116(22):4523\u20134531. https:\/\/doi.org\/10.1182\/blood-2010-02-267542","DOI":"10.1182\/blood-2010-02-267542"},{"issue":"4","key":"4018_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/1756-185X.12075","volume":"16","author":"N Suzuki","year":"2013","unstructured":"Suzuki N, Sasaki N, Utsumi Y, Nagashima H, Nakamura Y, Yamashita M, Yamauchi K, Sawai T (2013) Effects of imatinib mesylate on pulmonary allergic vasculitis in a murine model. Int J Rheum Dis 16(4):455\u2013462. https:\/\/doi.org\/10.1111\/1756-185X.12075","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"4018_CR24","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1016\/j.transproceed.2009.02.100","volume":"41","author":"EB Tapper","year":"2009","unstructured":"Tapper EB, Knowles D, Heffron T, Lawrence EC, Csete M (2009) Portopulmonary hypertension: imatinib as a novel treatment and the Emory experience with this condition. Transplant Proc 41(5):1969\u20131971. https:\/\/doi.org\/10.1016\/j.transproceed.2009.02.100","journal-title":"Transplant Proc"},{"issue":"11","key":"4018_CR25","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1136\/ard.2007.070805","volume":"67","author":"E Lozano","year":"2008","unstructured":"Lozano E, Segarra M, Garc\u00eda-Mart\u00ednez A, Hern\u00e1ndez-Rodr\u00edguez J, Cid MC (2008) Imatinib mesylate inhibits in vitro and ex vivo biological responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis 67(11):1581\u20131588. https:\/\/doi.org\/10.1136\/ard.2007.070805","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4018_CR26","doi-asserted-by":"publisher","first-page":"836","DOI":"10.2174\/1570159X13666150518235504","volume":"13","author":"I G\u0105ga\u0142o","year":"2015","unstructured":"G\u0105ga\u0142o I, Rusiecka I, Koci\u0107 I (2015) Tyrosine kinase inhibitor as a new therapy for ischemic stroke and other neurologic diseases: is there any hope for a better outcome? Curr Neuropharmacol 13(6):836\u2013844. https:\/\/doi.org\/10.2174\/1570159X13666150518235504","journal-title":"Curr Neuropharmacol"},{"issue":"9","key":"4018_CR27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1093\/rheumatology\/kev242","volume":"54","author":"G Emmi","year":"2015","unstructured":"Emmi G, Silvestri E, Marconi R, Carrai V, Fanelli T, Zucchini P, Marasca R, Vannucchi AM, Emmi L, Prisco D, Vaglio A (2015) First report of FIP1L1-PDGFR\u03b1-positive eosinophilic granulomatosis with polyangiitis. Rheumatol (United Kingdom) 54(9):1751\u20131753. https:\/\/doi.org\/10.1093\/rheumatology\/kev242","journal-title":"Rheumatol (United Kingdom)"},{"issue":"5","key":"4018_CR28","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3109\/s10165-009-0193-x","volume":"19","author":"F Terabe","year":"2009","unstructured":"Terabe F, Kitano M, Kawai M, Kuwahara Y, Hirano T, Arimitsu J, Hagihara K, Shima Y, Narazaki M, Tanaka T, Kawase I, Sano H, Ogata A (2009) Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway. Mod Rheumatol 19(5):522\u2013529. https:\/\/doi.org\/10.1007\/s10165-009-0193-x","journal-title":"Mod Rheumatol"},{"issue":"11","key":"4018_CR29","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1164\/rccm.200404-531OC","volume":"171","author":"Y Aono","year":"2005","unstructured":"Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S (2005) Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171(11):1279\u20131285. https:\/\/doi.org\/10.1164\/rccm.200404-531OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4018_CR30","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1167\/iovs.08-2443","volume":"50","author":"L Steensel van","year":"2009","unstructured":"van Steensel L, Paridaens D, Schrijver B, Dingjan GM, van Daele PLA, Martin van Hagen P et al (2009) Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves\u2019 ophthalmopathy. Invest Ophthalmol Vis Sci 50(7):3091\u20133098. https:\/\/doi.org\/10.1167\/iovs.08-2443","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"4018_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.04-2370com","volume":"19","author":"S Wang","year":"2005","unstructured":"Wang S (2005) Imatinib mesylate blocks a non-Smad TGF- pathway and reduces renal fibrogenesis in vivo. FASEB J 19(1):1\u201311. https:\/\/doi.org\/10.1096\/fj.04-2370com","journal-title":"FASEB J"},{"issue":"10","key":"4018_CR32","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/1440-1681.12286","volume":"41","author":"GE Shiha","year":"2014","unstructured":"Shiha GE, Abu-Elsaad NM, Zalata KR, Ibrahim TM (2014) Tracking anti-fibrotic pathways of nilotinib and imatinib in experimentally induced liver fibrosis: an insight. Clin Exp Pharmacol Physiol 41(10):788\u2013797. https:\/\/doi.org\/10.1111\/1440-1681.12286","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"4018_CR33","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.29957","volume":"62","author":"RF Spiera","year":"2010","unstructured":"Spiera RF, Gordon JK, Mersten J, Magro C, Mehta M, Wildman H et al (2010) Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a one year, phase IIa, single arm, open label clinical trial. Arthritis Rheum 62:2193. https:\/\/doi.org\/10.1002\/art.29957","journal-title":"Arthritis Rheum"},{"issue":"1","key":"4018_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/art.24186","volume":"60","author":"A Akhmetshina","year":"2009","unstructured":"Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JHW (2009) Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum 60(1):219\u2013224. https:\/\/doi.org\/10.1002\/art.24186","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4018_CR35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11605-011-1764-7","volume":"16","author":"WL Kuo","year":"2012","unstructured":"Kuo WL, Yu MC, Lee JF, Tsai CN, Chen TC, Chen MF (2012) Imatinib mesylate improves liver regeneration and attenuates liver fibrogenesis in CCL 4-treated mice. J Gastrointest Surg 16(2):361\u2013369. https:\/\/doi.org\/10.1007\/s11605-011-1764-7","journal-title":"J Gastrointest Surg"},{"issue":"6","key":"4018_CR36","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/j.1468-3083.2011.04398.x","volume":"27","author":"TR Elmholdt","year":"2013","unstructured":"Elmholdt TR, Buus NH, Ramsing M, Olesen AB (2013) Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial. J Eur Acad Dermatol Venereol 27(6):779\u2013784. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04398.x","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"4018_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.semarthrit.2012.06.001","volume":"42","author":"VK Bournia","year":"2013","unstructured":"Bournia VK, Evangelou K, Sfikakis PP (2013) Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with Imatinib. Semin Arthritis Rheum 42(4):377\u2013390. https:\/\/doi.org\/10.1016\/j.semarthrit.2012.06.001","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"4018_CR38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10067-012-2032-2","volume":"31","author":"L Guo","year":"2012","unstructured":"Guo L, Chen XX, Gu YY, Zou HJ, Ye S (2012) Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clin Rheumatol 31(9):1395\u20131400. https:\/\/doi.org\/10.1007\/s10067-012-2032-2","journal-title":"Clin Rheumatol"},{"issue":"3","key":"4018_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3109\/09553002.2013.741281","volume":"89","author":"JA Horton","year":"2013","unstructured":"Horton JA, Chung EJ, Hudak KE, Sowers A, Thetford A, White AO, Mitchell JB, Citrin DE (2013) Inhibition of radiation-induced skin fibrosis with imatinib. Int J Radiat Biol 89(3):162\u2013170. https:\/\/doi.org\/10.3109\/09553002.2013.741281","journal-title":"Int J Radiat Biol"},{"issue":"6","key":"4018_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","volume":"181","author":"CE Daniels","year":"2010","unstructured":"Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, Imatinib-IPF Study Investigators (2010) Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6):604\u2013610. https:\/\/doi.org\/10.1164\/rccm.200906-0964OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4018_CR41","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/j.1365-2133.2012.11186.x","volume":"167","author":"S Prey","year":"2012","unstructured":"Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Hachulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, Seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Ta\u00efeb A (2012) Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 167(5):1138\u20131144. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11186.x","journal-title":"Br J Dermatol"},{"issue":"9","key":"4018_CR42","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1093\/ndt\/gfq790","volume":"26","author":"J Savikko","year":"2011","unstructured":"Savikko J, Rintala JM, Rintala SE, Koskinen PK, von Willebrand E (2011) Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy. Nephrol Dial Transplant 26(9):3026\u20133032. https:\/\/doi.org\/10.1093\/ndt\/gfq790","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"4018_CR43","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.ki.5001528","volume":"70","author":"C Zoja","year":"2006","unstructured":"Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G (2006) Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70(1):97\u2013103. https:\/\/doi.org\/10.1038\/sj.ki.5001528","journal-title":"Kidney Int"},{"issue":"12","key":"4018_CR44","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1002\/art.21424","volume":"52","author":"A Sadanaga","year":"2005","unstructured":"Sadanaga A, Nakashima H, Masutani K, Miyake K, Shimizu S, Igawa T, Sugiyama N, Niiro H, Hirakata H, Harada M (2005) Amelioration of autoimmune nephritis by imatinib in MRL\/lpr mice. Arthritis Rheum 52(12):3987\u20133996. https:\/\/doi.org\/10.1002\/art.21424","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4018_CR45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.ASN.0000108522.79652.63","volume":"15","author":"KL Hudkins","year":"2004","unstructured":"Hudkins KL, Gilbertson DG, Carling M, Taneda S, Hughes SD, Holdren MS, Palmer TE, Topouzis S, Haran AC, Feldhaus AL, Alpers CE (2004) Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J Am Soc Nephrol 15(2):286\u2013298. https:\/\/doi.org\/10.1097\/01.ASN.0000108522.79652.63","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"4018_CR46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1046\/j.1523-1755.2003.00778.x","volume":"63","author":"S Taneda","year":"2003","unstructured":"Taneda S, Hudkins KL, Cui Y, Farr AG, Alpers CE, Segerer S (2003) Growth factor expression in a murine model of cryoglobulinemia. Kidney Int 63(2):576\u2013590. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00778.x","journal-title":"Kidney Int"},{"issue":"1","key":"4018_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1681\/ASN.2008010036","volume":"20","author":"M Iyoda","year":"2009","unstructured":"Iyoda M, Hudkins KL, Becker-Herman S, Wietecha TA, Banas MC, Guo S, Meyer-Bahlburg A, Kowalewska J, Liu G, Ziegler SF, Rawlings DJ, Alpers CE (2009) Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. J Am Soc Nephrol 20(1):68\u201377. https:\/\/doi.org\/10.1681\/ASN.2008010036","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"4018_CR48","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1084\/jem.20031983","volume":"199","author":"V Agosti","year":"2004","unstructured":"Agosti V, Corbacioglu S, Ehlers I, Waskow C, Sommer G, Berrozpe G, Kissel H, Tucker CM, Manova K, Moore MAS, Rodewald HR, Besmer P (2004) Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J Exp Med 199(6):867\u2013878. https:\/\/doi.org\/10.1084\/jem.20031983","journal-title":"J Exp Med"},{"issue":"3","key":"4018_CR49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/intimm\/dxl143","volume":"19","author":"QLK Lam","year":"2007","unstructured":"Lam QLK, Lo CKC, Zheng BJ, Ko KH, Osmond DG, Wu GE, Rottapel R, Lu L (2007) Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice. Int Immunol 19(3):267\u2013276. https:\/\/doi.org\/10.1093\/intimm\/dxl143","journal-title":"Int Immunol"},{"issue":"1","key":"4018_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1053\/j.ajkd.2011.08.016","volume":"59","author":"E Wallace","year":"2012","unstructured":"Wallace E, Fogo AB, Schulman G (2012) Imatinib therapy for non-infection-related type II cryoglobulinemia with membranoproliferative glomerulonephritis. Am J Kidney Dis 59(1):122\u2013125. https:\/\/doi.org\/10.1053\/j.ajkd.2011.08.016","journal-title":"Am J Kidney Dis"},{"key":"4018_CR51","unstructured":"Scheinfeld N (2006) Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. Vol. 5, J Drugs Dermat: JDD. p. 228\u201331"},{"issue":"10","key":"4018_CR52","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2006-04-018705","volume":"108","author":"S Mumprecht","year":"2006","unstructured":"Mumprecht S, Matter M, Pavelic V, Ochsenbein AF (2006) Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108(10):3406\u20133413. https:\/\/doi.org\/10.1182\/blood-2006-04-018705","journal-title":"Blood"},{"issue":"5","key":"4018_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chom.2011.09.010","volume":"10","author":"RJ Napier","year":"2011","unstructured":"Napier RJ, Rafi W, Cheruvu M, Powell KR, Zaunbrecher MA, Bornmann W, Salgame P, Shinnick TM, Kalman D (2011) Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis. Cell Host Microbe 10(5):475\u2013485. https:\/\/doi.org\/10.1016\/j.chom.2011.09.010","journal-title":"Cell Host Microbe"},{"issue":"1","key":"4018_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-005-1084-7","volume":"85","author":"AMS M\u00fcller","year":"2006","unstructured":"M\u00fcller AMS, Martens UM, Hofmann SC, Bruckner-Tuderman L, Mertelsmann R, L\u00fcbbert M (2006) Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature. Ann Hematol 85(1):1\u201316. https:\/\/doi.org\/10.1007\/s00277-005-1084-7","journal-title":"Ann Hematol"},{"issue":"9","key":"4018_CR55","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.3324\/haematol.11420","volume":"92","author":"M Baccarani","year":"2007","unstructured":"Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S, Tiribelli M, Buccisano F, Testoni N, Gottardi E, de Vivo A, Giugliano E, Iacobucci I, Paolini S, Soverini S, Rosti G, Rancati F, Astolfi C, Pane F, Saglio G, Martinelli G (2007) The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR\u03b1-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 92(9):1173\u20131179. https:\/\/doi.org\/10.3324\/haematol.11420","journal-title":"Haematologica"},{"issue":"6","key":"4018_CR56","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/all.12843","volume":"71","author":"P Khoury","year":"2016","unstructured":"Khoury P, Desmond R, Pabon A, Holland-Thomas N, Ware JM, Arthur DC, Kurlander R, Fay MP, Maric I, Klion AD (2016) Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy Eur J Allergy Clin Immunol 71(6):803\u2013810. https:\/\/doi.org\/10.1111\/all.12843","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"4018_CR57","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.ejim.2016.02.024","volume":"32","author":"G Helbig","year":"2016","unstructured":"Helbig G (2016) Imatinib mesylate for unmutated hypereosinophilic syndromes: does it work? Eur J Intern Med 32:e19\u2013e20. https:\/\/doi.org\/10.1016\/j.ejim.2016.02.024","journal-title":"Eur J Intern Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4018-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4018-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T22:12:18Z","timestamp":1751494338000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4018-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4018"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4018-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"8 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Our study complies with the Declaration of Helsinki; the approval for this study was not required in accordance with the policy of your institution; and the informed consent has been obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Helsinki"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}